Intraocular Inflammation, Safety Events, and Outcomes After IVT Injection of Ranibizumab, Aflibercept, Brolucizumab, Abicipar Pegol, and Faricimab for nAMD

On this episode of the JVRD Author’s Forum podcast, Dr. Marta Stevanovic of the Massachusetts Eye and Ear Infirmary at Harvard Medical School discusses “Intraocular Inflammation, Safety Events, and Outcomes After Intravitreal Injection of Ranibizumab, Aflibercept, Brolucizumab, Abicipar Pegol, and Faricimab for nAMD,” published in the July/August 2025 issue of JVRD.Host Dr. Timothy Murray and Dr. Stevanovic review her team’s network meta-analysis of phase 3 clinical trial data comparing anti-VEGF agents used for neovascular AMD. Hear what the study reveals about the relative risk of intraocular inflammation, endophthalmitis, vasculitis, and other events, why real-world experience still matters, and how these findings can guide clinicians in their use of anti-VEGF therapies.For more information, visit www.ASRS.org/JVRDForum.Welcome to ASRS’s Journal of Vitreoretinal Diseases (JVRD) Author’s Forum. JVRD is the official scientific peer-reviewed journal of the American Society of Retina Specialists (ASRS), offering the highest quality and most impactful research and clinical information in the field. Join host Dr. Timothy Murray, Editor-in-Chief of JVRD, as he discusses cutting-edge developments featured in JVRD with the lead authors, who share clinical pearls and explore their significance in advancing patient care.

There are no comments yet.

Please log in to write the first comment.